Skip to main content
Erschienen in: Journal of Cancer Education 3/2019

15.01.2018

Prostate Cancer Patients’ Understanding of the Gleason Scoring System: Implications for Shared Decision-Making

verfasst von: Erin K. Tagai, Suzanne M. Miller, Alexander Kutikov, Michael A. Diefenbach, Ronak A. Gor, Tahseen Al-Saleem, David Y. T. Chen, Sara Fleszar, Gem Roy

Erschienen in: Journal of Cancer Education | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

The Gleason scoring system is a key component of a prostate cancer diagnosis, since it indicates disease aggressiveness. It also serves as a risk communication tool that facilitates shared treatment decision-making. However, the system is highly complex and therefore difficult to communicate: factors which have been shown to undermine well-informed and high-quality shared treatment decision-making. To systematically explore prostate cancer patients’ understanding of the Gleason scoring system (GSS), we assessed knowledge and perceived importance among men who had completed treatment (N = 50). Patients were administered a survey that assessed patient knowledge and patients’ perceived importance of the GSS, as well as demographics, medical factors (e.g., Gleason score at diagnosis), and health literacy. Bivariate analyses were conducted to identify associations with patient knowledge and perceived importance of the GSS. The sample was generally well-educated (48% with a bachelor’s degree or higher) and health literate (M = 12.9, SD = 2.2, range = 3–15). Despite this, patient knowledge of the GSS was low (M = 1.8, SD = 1.4, range = 14). Patients’ understanding of the importance of the GSS was moderate (M = 2.8, SD = 1.0, range = 0–4) and was positively associated with GSS knowledge (p < .01). Additionally, GSS knowledge was negatively associated with years since biopsy (p < .05). Age and health literacy were positively associated with patients’ perceived importance of the GSS (p < .05), but not with GSS knowledge. Patient knowledge is thus less than optimal and would benefit from enhanced communication to maximize shared treatment decision-making. Future studies are needed to explore the potential utility of a simplified Gleason grading system and improved patient-provider communication.
Literatur
4.
Zurück zum Zitat McDougal, W Scott, Alan J Wein, Louis R Kavoussi, Andrew C Novick, Alan W Partin, Craig A Peters, and Parvati Ramchandani (2011) Campbell-Walsh urology 10th edition review. Elsevier Health Sciences McDougal, W Scott, Alan J Wein, Louis R Kavoussi, Andrew C Novick, Alan W Partin, Craig A Peters, and Parvati Ramchandani (2011) Campbell-Walsh urology 10th edition review. Elsevier Health Sciences
7.
Zurück zum Zitat Ozok HU, Sagnak L, Tuygun C, Oktay M, Karakoyunlu N, Ersoy H, Murat Alper (2009) Will the modification of the Gleason grading system affect the urology practice? Int J Surg Pathol Ozok HU, Sagnak L, Tuygun C, Oktay M, Karakoyunlu N, Ersoy H, Murat Alper (2009) Will the modification of the Gleason grading system affect the urology practice? Int J Surg Pathol
8.
Zurück zum Zitat Ernstmann N, Weissbach L, Herden J, Winter N, Ansmann L (2016) Patient-physician-communication and health related quality of life of localized prostate cancer patients undergoing radical prostatectomy—a longitudinal multilevel analysis. BJU Int 119(3):396–405. https://doi.org/10.1111/bju.13495 CrossRefPubMed Ernstmann N, Weissbach L, Herden J, Winter N, Ansmann L (2016) Patient-physician-communication and health related quality of life of localized prostate cancer patients undergoing radical prostatectomy—a longitudinal multilevel analysis. BJU Int 119(3):396–405. https://​doi.​org/​10.​1111/​bju.​13495 CrossRefPubMed
11.
Zurück zum Zitat Chew LD, Bradley KA, Boyko EJ (2004) Brief questions to identify patients with inadequate health literacy. Fam Med 36(8):588–594PubMed Chew LD, Bradley KA, Boyko EJ (2004) Brief questions to identify patients with inadequate health literacy. Fam Med 36(8):588–594PubMed
17.
Zurück zum Zitat Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69(3):428–435. https://doi.org/10.1016/j.eururo.2015.06.046. CrossRef Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69(3):428–435. https://​doi.​org/​10.​1016/​j.​eururo.​2015.​06.​046.​ CrossRef
18.
Zurück zum Zitat Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244–252. https://doi.org/10.1097/pas.0000000000000530. CrossRef Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA (2016) The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244–252. https://​doi.​org/​10.​1097/​pas.​0000000000000530​.​ CrossRef
24.
Zurück zum Zitat Colella KM, DeLuca G (2004) Shared decision making in patients with newly diagnosed prostate cancer: a model for treatment education and support. Urol Nurs 24(3):187–191 195-186PubMed Colella KM, DeLuca G (2004) Shared decision making in patients with newly diagnosed prostate cancer: a model for treatment education and support. Urol Nurs 24(3):187–191 195-186PubMed
Metadaten
Titel
Prostate Cancer Patients’ Understanding of the Gleason Scoring System: Implications for Shared Decision-Making
verfasst von
Erin K. Tagai
Suzanne M. Miller
Alexander Kutikov
Michael A. Diefenbach
Ronak A. Gor
Tahseen Al-Saleem
David Y. T. Chen
Sara Fleszar
Gem Roy
Publikationsdatum
15.01.2018
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 3/2019
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-018-1320-1

Weitere Artikel der Ausgabe 3/2019

Journal of Cancer Education 3/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.